-- 
Teva, Financial Levers, Paz Oil, Protalix: Israel Equity Movers

-- B y   G w e n   A c k e r m a n
-- 
2011-07-17T15:00:18Z

-- http://www.bloomberg.com/news/2011-07-17/teva-financial-levers-paz-oil-co-israel-equity-movers.html
Israel’s TA-25 Index lost less than
0.1 percent to 1,251.14 at the 4:30 p.m. close in  Tel Aviv . The
following stocks rose or fell today. Symbols are in parentheses.  Africa-Israel Investments Ltd. (AFIL)   increased 2.1
percent to 22.16 shekels, its biggest gain since July 7. The
holding company’s Africa Israel Properties Ltd. unit said it
completed a 840 million-shekel ($244 million) refinancing
agreement for an office building in Tel Aviv.  Financial Levers Ltd. (LVR)   slumped 8.5 percent to 0.75
shekel, its lowest price in 17 months. The  investment company 
said that the Israel Securities Authority searched its offices
on July 13 and confiscated documents.  Paz Oil Co. (PZOL IT) fell 0.9 percent to 570 shekels, the
largest retreat since July 11. The maker of petroleum-based
products said an International Air Transport Association report
published on July 15 didn’t contain information finding the
company at fault for contaminated  jet fuel  that stopped air
traffic in Israel in early May.       Protalix BioTherapeutics Ltd. (PLX IT) decreased 2.8
percent to 23.30 shekels, the biggest decline since June 12.
 Biocell Ltd. (BCEL)   slipped 1.6 percent to 29.35 shekels
after saying its board decided to keep a 17 percent stake in the
investment company.  Teva Pharmaceutical Industries Ltd. (TEVA)   slid 2.6
percent to 165 shekels, its largest drop in four weeks. A U.S.
district court found the world’s biggest maker of generic drugs
infringed Amgen Inc. patents.  The court issued an injunction preventing Teva from selling
its Neutroval treatment in the U.S. until Nov. 10, 2013,
according to a PR Newswire statement. Teva also agreed not to
sell its Neugranin medicine until the same date.  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  